| Year (season) | No of infants administered palivuzumab | No of infants admitted with RSV bronchiolitis | Age range treated at start of season |
|---|---|---|---|
| 2004/5 (Preclinic) | 7 | 1 | 6–20 months |
| 2005/6 (Preclinic) | 8 | 4 | 4–32 months |
| 2006/7 | 6 | 0 | 4–15 months |
| 2007/8 | 10 | 0 | 2–21 months |
| 2008/9 | 10 | 0 | 1–12 months |
| 2009/10 | 9 | 0 | 1–9 months |
| Preclinic results (2004/5-2005/6) | Clinic results (2006/7–2009/10) | ||
| No of infants | 15 | 35 | |
| Dose range | 45–200 mg | 27–180 mg | |
| Hospital admissions | 5 | 0 | |
| Dose interval | 23–38 days | 28 days | |
| Adverse events | None | None |